Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Nanoscope-Therapeutic

More Like This

PR Newswire associated0

HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS

Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference

Axovia Therapeutics Announces Presentation of Preclinical Data Supporting Lead Program AXV-101 for Treatment of Blindness Associated with BBS1 Mutations at ASGCT

PR Newswire associated0

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C

RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort